Literature DB >> 25558293

Salutary effect of pre-treatment with an Nrf2 inducer on ischemia reperfusion injury in the rat liver.

Yuichi Masuda1, Nosratola D Vaziri1, Chie Takasu1, Shiri Li1, Lourdes Robles1, Christine Pham1, Aimee Le1, Kelly Vo1, Seyed H Farzaneh1, Michael J Stamos1, Hirohito Ichii1.   

Abstract

BACKGROUND: Ischemia-reperfusion injury (IRI) is a common phenomenon occurring during liver surgery, transplantation, and trauma. IRI causes oxidative stress which plays a critical role in causing organ damage. The Nrf2 is the master regulator of numerous genes, encoding antioxidant, detoxifying, and cytoprotective molecules. Nrf2 dysfunction has been implicated in the pathogenesis of several inflammatory disorders, cancer, and aging. This study was undertaken to investigate the effect of Nrf2 pathway activator (dh404) on warm liver IRI in a rodent model.
METHODS: Ten Sprague-Dawley rats were treated with dh404 or vehicle. Dh404 was dissolved in sesame oil and was given orally (1.5mg/kg) the night before and 5 hours before procedures. Rat livers were subjected to 60 minutes of 70% ischemia followed by 3 hours of reperfusion. Serum ALT and Malondialdehyde (MDA) were determined and liver tissue was processed for histological examination, and determination of apoptosis, myeloperoxidase (MPO) activity, ADP/ATP ratio, and expressions of Nrf2, eNOS, anti-oxidant enzymes, and inflammatory mediators.
RESULTS: Serum ALT and MDA levels and tissue MPO activity were significantly lower, expression of the anti-oxidant enzyme, glutamate cysteine ligase were significantly higher, whereas expression of NFkB and COX-2 was unchanged in the dh404-treated group. Although the total Suzuki histology score did not differ significantly, the extent of sinusoidal congestion, vacuolization, and apoptosis was significantly reduced in the dh404 treated compared to the untreated group (P<0.01).
CONCLUSIONS: Pre-treatment with dh404 resulted in partial attenuation of hepatic ischemia reperfusion injury in rats.

Entities:  

Keywords:  Reactive Oxygen Species; bardoxolone methyl analogue; inflammation; ischemia reperfusion injury; liver; oxidative stress

Year:  2014        PMID: 25558293      PMCID: PMC4280567          DOI: 10.3968/5206

Source DB:  PubMed          Journal:  Gastroenterol Hepatol (Que)


  24 in total

1.  Liver ischaemia and reperfusion injury.

Authors:  R Busuttil
Journal:  Br J Surg       Date:  2007-07       Impact factor: 6.939

Review 2.  Nrf2 the rescue: effects of the antioxidative/electrophilic response on the liver.

Authors:  Curtis D Klaassen; Scott A Reisman
Journal:  Toxicol Appl Pharmacol       Date:  2010-02-01       Impact factor: 4.219

Review 3.  Nrf2-ARE signaling pathway and natural products for cancer chemoprevention.

Authors:  Cui Rong Zhao; Zu Hua Gao; Xian Jun Qu
Journal:  Cancer Epidemiol       Date:  2010-07-17       Impact factor: 2.984

4.  KEAP1-NRF2 complex in ischemia-induced hepatocellular damage of mouse liver transplants.

Authors:  Bibo Ke; Xiu-Da Shen; Yu Zhang; Haofeng Ji; Feng Gao; Shi Yue; Naoko Kamo; Yuan Zhai; Masayuki Yamamoto; Ronald W Busuttil; Jerzy W Kupiec-Weglinski
Journal:  J Hepatol       Date:  2013-07-16       Impact factor: 25.083

5.  The beneficial effect of a prostaglandin I2 analog on ischemic rat liver.

Authors:  S Suzuki; S Nakamura; T Koizumi; S Sakaguchi; S Baba; H Muro; Y Fujise
Journal:  Transplantation       Date:  1991-12       Impact factor: 4.939

6.  Myeloperoxidase activity as a quantitative assessment of neutrophil infiltration into ischemic myocardium.

Authors:  K M Mullane; R Kraemer; B Smith
Journal:  J Pharmacol Methods       Date:  1985-11

7.  Bardoxolone methyl (BARD) ameliorates aristolochic acid (AA)-induced acute kidney injury through Nrf2 pathway.

Authors:  Juan Wu; Xinhui Liu; Jinjin Fan; Wenfang Chen; Juan Wang; Youjia Zeng; Xiaorang Feng; Xueqing Yu; Xiao Yang
Journal:  Toxicology       Date:  2014-02-12       Impact factor: 4.221

8.  Nrf2 is overexpressed in pancreatic cancer: implications for cell proliferation and therapy.

Authors:  Adam Lister; Taoufik Nedjadi; Neil R Kitteringham; Fiona Campbell; Eithne Costello; Bryony Lloyd; Ian M Copple; Samantha Williams; Andrew Owen; John P Neoptolemos; Chris E Goldring; B Kevin Park
Journal:  Mol Cancer       Date:  2011-04-13       Impact factor: 27.401

Review 9.  The current state of knowledge of hepatic ischemia-reperfusion injury based on its study in experimental models.

Authors:  M Mendes-Braz; M Elias-Miró; M B Jiménez-Castro; A Casillas-Ramírez; F S Ramalho; C Peralta
Journal:  J Biomed Biotechnol       Date:  2012-05-09

10.  The synthetic triterpenoid RTA dh404 (CDDO-dhTFEA) restores Nrf2 activity and attenuates oxidative stress, inflammation, and fibrosis in rats with chronic kidney disease.

Authors:  Mohammad A Aminzadeh; Scott A Reisman; Nosratola D Vaziri; Mahyar Khazaeli; Jun Yuan; Colin J Meyer
Journal:  Xenobiotica       Date:  2013-11-06       Impact factor: 1.908

View more
  3 in total

1.  Treatment with dimethyl fumarate ameliorates liver ischemia/reperfusion injury.

Authors:  Chie Takasu; Nosratola D Vaziri; Shiri Li; Lourdes Robles; Kelly Vo; Mizuki Takasu; Christine Pham; Seyed H Farzaneh; Mitsuo Shimada; Michael J Stamos; Hirohito Ichii
Journal:  World J Gastroenterol       Date:  2017-07-07       Impact factor: 5.742

2.  Curcumin-carrying nanoparticles prevent ischemia-reperfusion injury in human renal cells.

Authors:  Yong Xu; Ning Hu; Wei Jiang; Hong-Fang Yuan; Dong-Hui Zheng
Journal:  Oncotarget       Date:  2016-12-27

3.  Mesenchymal stem cells versus their conditioned medium in the treatment of ischemia/reperfusion injury: Evaluation of efficacy and hepatic specific gene expression in mice.

Authors:  Somayeh Khosravi-Farsani; Arash Zaminy; Sedigheh Kazemi; Morteza Hashemzadeh-Chaleshtori
Journal:  Iran J Basic Med Sci       Date:  2022-07       Impact factor: 2.532

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.